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1. Introduction 
Vasopressin, in amounts likely to be produced in 
haemorrhagic shock, causes glycogenolysis in the 
liver [ 1,2] through a prompt activation of liver 
glycogen phosphorylase (EC 2.4.1 .l) [3,4] . This 
activation, unlike that produced by glucagon or 
adrenaline, is not mediated by an enhanced activity 
of protein kinase (EC 2.7.1.37) [3] and neither does 
vasopressin increase the concentration of cyclic AMP 
in rat liver [5] . 
A haemorrhage results in an increase of the blood 
levels of angiotensin II (for recent reviews see [6,7 ] ) 
and the question arises naturally whether angiotensin 
II shares the glycogenolytic properties of vasopressin. 
Conflicting reports can be found in the literature 
concerning an effect of angiotensin II on blood sugar 
level, which has been reported to rise [g-10] , to 
remain unaltered [l I-131 or even to decline [14] 
after the injection of the octapeptide. It should 
however been noted that those authors who did not 
find a hyperglycemic response to angiotensin II 
[ 1 1 - 141 have been using fasting animals or subjects, 
so that the lack of a systemic hyperglycemia can 
conceivably stem from unsufficient liver glycogen 
stores. It has indeed been shown [8] that the 
hyperglycemia caused by angiotensin II is accompanied 
with a progressive loss of liver, but not of muscle, 
glycogen. Furthermore, two groups of investigators 
have presented evidence for a direct glycogenolytic 
effect of angiotensin II on isolated rat liver prepara- 
tions [8,10]. We report here that, as vasopressin, 
angiotensin II causes a direct activation of liver 
glycogen phosphorylase, the rate limiting enzyme for 
glycogenolysis; likewise, the mechanism involved 
North-Holland Publishing Company - Amsterdam 
appears to be cyclic AMP independent. Preliminary 
communications describe part of the data [ 15,161. 
2. Materials and methods 
Angiotensin 11 and its hexa$eptide were obtained 
from Schwarz-Mann (Orangeburg, N.Y.) I-Sar-8-Ile- 
angiotensin II was a gift of Dr. F. M. Bumpus 
(Cleveland Clinic, Cleveland). 
All techniques including the experiments with 
intact rats with isolated hepatocytes and the enzyme 
assays have been described or referred to [3,17,18]. 
3. Results 
3.1. Experiments with intact anaesthetized rats 
Angiotensin II (0.2 or 0.4 lg per rat) caused a 
prompt activation of liver glycogen phosphorylase 
which was already evident after 20 set and reached 
plateau levels between 30 and 60 set (fig.1). This 
rate of activation compares favourably with those 
obtained with either vasopressin or with glucagon [3]. 
The hexapeptide derived from angiotensin II is 
endowed with much less pressor activity (see [6,7]); 
likewise, its glycogenolytic potency is also less marked: 
fig.1 shows that 0.4 pg of the hexapeptide did not 
activate liver glycogen phosphorylase. 
The mode of action of angiotensin II resembles that 
of vasopressin [3,5] ; indeed, no change occurred in 
the activity of the protein kinase measured with 
histone f2b or II, as the substrate and without added 
cyclic AMP (cyclic AMP independent activity); neither 
was there, as expected, an increase in total protein 
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Fig. 1. The influence of angiotensin II on the level of liver 
glycogen phosphorylase. The octapeptide (0.4 pg), the 
hexapeptide (0.4 pg) or the corresponding saline solution 
(1.5 ml) was injected intravenously into an anaesthetized 
rat. In each experiment, liver biopsies from the same animal 
were taken at various time intervals. 
Fig.2. Kinetics of the activation of glycogen phosphorylase 
by angiotensin II in isolated liver cells. Liver cells (lO’/ml) 
were preincubated for 30-45 min with 20 mM glucose; 
phosphorylase a levels were measured in aliquots taken at 
the indicated time intervals after the addition of angiotensin 
II (20 ng/ml). Results shown are the means of 8 experiments 
kinase activity, as assayed with 10m6M cyclic nucleo- 
tide (table 1). We conclude therefore that, like vaso- 
pressin [ 3,s ] , angiotensin activates liver glycogen 
phosphorylase by a mechanism which appears not to 
be mediated by cyclic AMP. 
3.2. Experiments with isolated liver cells 
The rapidity of onset in vivo of the activation of 
liver glycogen phosphorylase by angiotensin II (fig. 1) 
clearly suggests a direct action on the liver. We corro- 
borate this proposal by showing in fig.2 that isolated 
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The effect of angiotensin II on liver glycogen phosphorylase and 
protein kinase in intact anaesthetized rats 
Enzyme 
Glycogen phosphorylase 
(U/g liver) 
CAMP Before 
7.0 + 0.7 
After 
16.0a + 0.7 
Protein kinase with f2b - 45 *4 43 +4 
(mu/g liver) + 204 + 3 197 *7 
with IIA - 30 t3 30 *3 
+ 87 +4 79 *3 
Two liver samples were taken from the same rat, one before and the other 1 min 
after the intravenous injection of 0.4 pg angiotensin II. Protein kinase was 
assayed with and without added cyclic AMP (10e6M), with histones f2b or IIA as 
the substrate [ 31. Values shown are means of 9 experiments (+- S.E.M.). Statistical 
significance was calculated from paired data. 
a P < 0.005. 
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Fig.3. Dose-response curve for the activation of liver dycogen 
phosphorylase by angiotensin II. Same procedure as in fig.2; 
samples were taken before and 1 min after the addition of 
angiotensin II at the indicated concentrations (0) without 
or (0) with 1-Sar-&Be-angiotensin II (8-Ile) at 200 ng/ml. 
rat liver parenchymal cells reacted to the addition of 
angiotensin II by a prompt activation of glycogen 
phosphorylase. This enzymic conversion occurred as 
rapidly as with glucagon (2X lo-’ M) and to approxi- 
mately the same extent [ 181. A typical dose effect 
curve (fig.3) showed that half-maximal ctivation 
was obtained with about 0.3 ng/ml. 
A known inhibitor of angiotensin II action, 
1-Sar-8-Ile [ 191 was able to prevent he activation of 
glycogen phosphorylase by increasing concentrations 
of angiotensin II, while having no activating effect on 
the enzyme by itself (fig.3). 
In confirmation and extension of the data obtained 
in vivo, angiotensin II did not activate liver protein 
kinase, as measured with histone f2b and without 
added cyclic AMP (table 2). 
4. Discussion 
The in vivo and in vitro experiments reported 
here show that angiotensin II shares the glyco- 
genolytic properties of vasopressin as previously 
reported both for the intact rat and for perfused 
liver [l-4] . As Was the case with the antidiuretic 
hormone [3], no increase in the cyclic AMP dependent 
protein kinase was induced by angiotensin II which 
therefore stimulates the conversion of phosphorylase 
b to a in a cyclic AMP independent way. Whether 
vasopressin and angiotensin II share a common mode 
of action remains to be elucidated. 
The amounts of angiotensin II required to obtain 
this activation of glycogen phosphorylase are likely 
to be produced in haemorrhagic conditions. It has 
been estimated that in the dog a moderate 
haemorrhage (the withdrawal of 14-26 ml blood/kg) 
results in increases of the concentration of angiotensin 
II of 0.33 ng/ml blood [20] ; a more severe 
haemorrhage (between 28 and 37 ml/kg) yields 
Table 2 
The effect of angiotensin II on glycogen phosphorylase and 
protein kinase in isolated rat liver cells 
Enzyme activity 
(mlJ/mg liver protein) 
CAMP Before After 
Glycogen phosphorylase 
Protein kinase 
15.7 + 1.8 63.ga * 7.0 
- 0.14 + 0.03 0.15 * 0.02 
+ 0.82 * 0.05 0.78 i 0.07 
Two aliquots were taken, one before and the other 1 min after the addition of 20 ng 
angiotensin/ml. Protein kinase was assayed with and without cyclic AMP (10e6M) 
with histone f2b as the substrate [3,181. Values shown are means of 6 experiments 
f S.E.M. Statistical significance was calculated from paired data. 
a P < 0.005. 
281 
Volume 68, number 2 FEBS LETTERS October 1976 
concentrations of nearly 2 ng/ml [21]. Similar values 
were obtained by other authors 122-241. Since a 
half-maximal activation of glycogen phosphorylase 
was obtained with about 0.3 ng angiotensin II per ml 
cell suspension (fig.3), we conclude that the amounts 
of angiotensin II found to affect liver glycogen 
phosphorylase are likely to be encountered in 
haemorrhagic shock. 
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